Menopause, postmenopausal osteoporosis, and dental implantation: the role of menopausal hormone therapy
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.678
Abstract
The article summarizes current evidence on the impact of postmenopausal osteoporosis, menopause-related hormonal changes, and hormone therapy on dental implant outcomes. Epidemiology and pathogenesis of bone alterations are reviewed, with particular emphasis on the role of estrogen, progesterone, calcitonin, growth hormone, and insulin-like growth factor-1 (IGF-1) deficiency. Special attention is paid to the effects of menopausal hormone therapy and bioidentical forms of estradiol and progesterone on osteoporosis course and the effectiveness of dental implantation. The analysis highlights the risks of implant loss and the opportunities of interdisciplinary approach in dentistry and endocrinology to optimize implant osseointegration in postmenopausal women.
About the Authors
E. V. Medvedeva
Medsi Group of Companies JSC
Russian Federation
Russian Federation
Ekaterina V. Medvedeva, MD.
6 Marata Str., Saint Petersburg 101025, Russia
N. V. Ivanov
Medsi Group of Companies JSC; Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation; Andijan State Medical Institute
Russian Federation
Russian Federation
Nikita V. Ivanov, MD, PhD.
Scopus Author ID: 57221190481.
WoS ResearcherID: JRZ-0207-2023.
6 Marata Str., Saint Petersburg 101025, Russia;
41 Kirochnaya Str., Saint Petersburg 191015, Russia;
1 Atabekov Str., Andijan 170127, Republic of Uzbekistan
A. F. Vesnina
Dedov National Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Anna F. Vesnina, PhD.
11 Dmitry Ulyanov Str., Moscow 117036, Russia
E. A. Khromova
Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Elena A. Khromova, PhD.
41 Kirochnaya Str., Saint Petersburg 191015, Russia
Sh. K. Yusupova
Andijan State Medical Institute
Uzbekistan
Uzbekistan
Shakhnоza K. Yusupova, MD, Dr Sci Med.
Scopus Author ID: 59418272100.
WoS ResearcherID: AEX-6726-2022.
1 Atabekov Str., Andijan 170127, Republic of Uzbekistan
References
1. Baber R., Panay N., Fenton A. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.
2. Simonova G.I., Lila A.M., Toroptsova N.V., Benevolenskaya L.I. Osteoporosis: current state of the problem. [Osteoporoz: sovremennoe sostoyanie problemy]. Nauchno-prakticheskaya revmatologiya. 2019;57(6):653–60. (In Russ.). https://doi.org/10.17116/terarkh201789590-97.
3. Eastell R., Rosen C.J., Black D.M. et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.
4. Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):4–9. https://doi.org/10.1016/j.bone.2005.11.024.
5. Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11. https://doi.org/10.1016/j.ajog.2005.08.047.
6. Temmerman A., Rasmusson L., Kubler A., Thor A. A prospective, randomized, controlled clinical trial on the long-term effect of osteoporosis on implant treatment. Clin Oral Implants Res. 2017;28(2):171–80. https://doi.org/10.1177/0022034518798804.
7. Alsaadi G., Quirynen M., Komarek A., van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J Clin Periodontol. 2007;34(7):610–7. https://doi.org/10.1111/j.1600-051x.2007.01077.x
8. Hernlund E., Svedbom A., Ivergard M. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136. https://doi.org/10.1007/s11657-013-0136-1.
9. International Osteoporosis Foundation. Facts and statistics. Режим доступа: https://www.osteoporosis.foundation/facts-statistics. [Дата обращения: 28.08.2025].
10. Toroptsova N.V., Benevolenskaya L.I., Lila A.M. Prevalence of osteoporosis and fractures in the Russian Federation: data from a multicenter epidemiological study. [Rasprostranennost’ osteoporoza i perelomov v Rossiyskoy Federatsii: dannye mnogotsentrovogo epidemiologicheskogo issledovaniya]. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15–23. (In Russ.).
11. Dervis E. Oral implications of osteoporosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):349–56. https://doi.org/10.1016/j.tripleo.2005.04.010.
12. Zhu L., Zhou C., Chen S. et al. Osteoporosis and alveolar bone health in periodontitis niche: a predisposing factors-centered review. Cells. 2022;11(21):3380. https://doi.org/10.3390/cells11213380.
13. Khosla S., Oursler M.J., Monroe D.G. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–81. https://doi.org/10.1016/j.tem.2012.03.008.
14. Prior J.C., Seifert-Klauss V.R., Giustini D. et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 20171;17(3):146–54.
15. Prior J.C. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–74. https://doi.org/10.1080/13697137.2018.1467400.
16. Mills E.G., Yang L., Nielsen M.F. et al. The relationship between bone and reproductive hormones beyond estrogens and androgens. Endocr Rev. 2021;42(6):691–719. https://doi.org/10.1210/endrev/bnab015.
17. Sun L., Peng Y., Sharrow A.C. et al. FSH directly regulates bone mass. Cell. 2006;125(2):247–60. https://doi.org/10.1016/j.cell.2006.01.051.
18. Grey A.B. The skeletal effects of primary hyperparathyroidism. Baillieres Clin Endocrinol Metab. 1997;11(1):101–16. https://doi.org/10.1016/s0950-351x(97)80537-x.
19. Zaidi M., Moonga B.S., Huang C.L. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002;110(12):1769–71. https://doi.org/10.1172/jci17425.
20. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.
21. Rosen C.J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 1999;222(2):103–11. https://doi.org/10.3181/00379727-206-43726.
22. Zaidi M., Davies T.F., Zallone A. et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep. 2009;7(2):47–52. https://doi.org/10.1007/s11914-009-0009-0.
23. Arpaci D., Saglam F., Cuhaci F.N. et al. Serum testosterone does not affect bone mineral density in postmenopausal women. Arch Endocrinol Metab. 2015;59(4):292–6. https://doi.org/10.1590/2359-3997000000085.
24. Tao M.F., Sun D.M., Shao H.F. Low serum testosterone is associated with osteoporosis in postmenopausal women. Gynecol Endocrinol. 2022;38(5):409–13. https://doi.org/10.1080/09513590.2021.1930977.
25. Zhang H., Ma K., Li R.M. et al. Association between testosterone levels and bone mineral density in females aged 40-60 years from NHANES 2011-2016. Sci Rep. 202230;12(1):16426. https://doi.org/10.1038/s41598-022-21008-7.
26. Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595–611. https://doi.org/10.1016/j.ecl.2012.04.004.
27. Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–17. https://doi.org/10.1016/s0092-8674(02)01049-8.
28. Holick M.F. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. https://doi.org/10.1056/NEJMra070553.
29. Hoppé E., Bouvard B., Royer M. et al. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010;77(4):306–12. https://doi.org/10.1016/j.jbspin.2010.03.011.
30. Weitzmann M.N. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. https://doi.org/10.1155/2013/125705.
31. Jeffcoat M.K. Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol. 1998;3(1):312–21. https://doi.org/10.1902/annals.1998.3.1.312.
32. Dvorak G., Arnhart C., Heuberer S. et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study. J Clin Periodontol. 2011;38(10):950–5. https://doi.org/10.1111/j.1600-051X.2011.01772.x.
33. Karoussis I.K., Müller S., Salvi G.E. et al. Association between periodontal and peri-implant conditions: a 10-year prospective study. Clin Oral Implants Res. 2004;15(1):1–7. https://doi.org/10.1111/j.1600-0501.2004.00982.x.
34. Black D.M., Rosen C.J. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/nejmc1602599.
35. Ruggiero S.L., Dodson T.B., Fantasia J. et al. Medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. https://doi.org/10.1016/j.joms.2014.04.031.
36. Khan A.A., Morrison A., Hanley D.A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. https://doi.org/10.1002/jbmr.2405.
37. Kuchler U., Luvizuto E.R., Tangl S. et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011;90(8):1001–6. https://doi.org/10.1177/0022034511407920.
38. Bashutski J.D., Eber R.M., Kinney J.S. et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363(25):2396–405. https://doi.org/10.1056/NEJMoa1005361.
39. Miller P.D., Hattersley G., Riis B.J. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: the ACTIVE randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.
40. Tabatabai L., Cosman F., Curtis J.R. et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective. Analysis. Endocr Pract. 2025;31(2):159–68. https://doi.org/10.1016/j.eprac.2024.10.017.
41. Cosman F., Crittenden D.B., Adachi J.D. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.
42. McClung M.R., Grauer A., Boonen S. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.
43. Giro G., Chambrone L., Goldstein A. et al. Impact of menopause hormone therapy on dental implant outcomes: a 5-year prospective study. Clin Implant Dent Relat Res. 2019;21(5):936–44. https://doi.org/10.1111/cid.12779.
44. Stanczyk F.Z., Archer D.F., Bhavnani B.R. Ethinyl estradiol and 17β-estradiol in contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706–27. https://doi.org/10.1016/j.contraception.2012.12.011.
Review
For citations:
Medvedeva E.V., Ivanov N.V., Vesnina A.F., Khromova E.A., Yusupova Sh.K. Menopause, postmenopausal osteoporosis, and dental implantation: the role of menopausal hormone therapy. Obstetrics, Gynecology and Reproduction. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.678
Views:
57
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
